Processa Pharmaceuticals (PCSA) risk factors

49 risks, 10 new, 2 dropped, 5 reworded since the prior year. The company has added extensive new risks regarding a newly approved digital asset treasury reserve strategy, including custody, volatility, and SEC compliance. Financial disclosures show an accumulated deficit of $100.8 million at December 31, 2025, with cash expected to run out by the second quarter of 2026.

41 risks. Processa Pharmaceuticals relies on ongoing equity financing and faces substantial doubt about its ability to continue as a going concern with $1.2 million in cash at year-end 2024. Clinical development of cancer therapy drug candidates NGC-Cap, NGC-Gem, and NGC-Iri requires substantial capital and remains unproven. The company faces a potential Nasdaq delisting due to its common stock failing to maintain the $1.00 minimum bid price.